RESUMEN
A series of N(1)- and N(2)-propargylphenelzine derivatives and analogues (1-7) was synthesized. In addition to their activity as monoamine oxidase inhibitors, two of the compounds, N(1)- and N(2)-propargylphenelzines (3 and 6), were found to be potent at preventing DSP-4-induced noradrenaline (NA) depletion in mouse hippocampus, suggesting that they have neuroprotective properties.
Asunto(s)
Fármacos Neuroprotectores/síntesis química , Fenelzina/síntesis química , Animales , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Ratones , Inhibidores de la Monoaminooxidasa/síntesis química , Inhibidores de la Monoaminooxidasa/química , Fármacos Neuroprotectores/química , Norepinefrina/metabolismo , Fenelzina/análogos & derivados , Fenelzina/química , Fenelzina/farmacologíaRESUMEN
Alcoholic extracts of the roots and leaves of three Echinacea species (E. purpurea, E. angustifolia and E. pallida) were analysed for the presence of characteristic chemicals by HPLC directly coupled to ultraviolet absorbance and electrospray mass spectrometric detectors. The method permitted rapid characterization and tentative identification of a large number of caffeoyl conjugates and alkamides in all the samples investigated. The roots of the three species differed markedly in their contents of characteristic compounds. Cichoric acid and verbascoside predominated in extracts of E. purpurea root whereas cynarine and dodeca-2E,4E,8Z,10Z/E-tetraenoic acid isobutylamide were the major chemicals characteristic of E. angustifolia root extracts. Echinacoside and 6-O-caffeoylechinacoside predominated in extracts of E. pallida roots. Characteristic alkamides were also examined by electrospray tandem mass spectrometry (MS/MS) and these compounds provided characteristic fragmentation patterns. Extracts of the roots and leaves of all three species were found to have antioxidant properties in a free radical scavenging assay and in a lipid peroxidation assay.
Asunto(s)
Antioxidantes/farmacología , Echinacea/química , Extractos Vegetales/farmacología , Plantas Medicinales , Cromatografía Líquida de Alta Presión , Depuradores de Radicales Libres , Humanos , Peroxidación de Lípido , Espectrometría de Masas , Neuroblastoma/patología , Extractos Vegetales/química , Hojas de la Planta/química , Raíces de Plantas/química , Espectrofotometría Ultravioleta , Células Tumorales CultivadasRESUMEN
The effects of Ginkgo biloba leaf extract on rat brain or livermonoamine oxidase (MAO)-A and -B activity, biogenic amine concentration in nervous tissue, N-methyl-D-aspartate (NMDA)- and N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4)-induced neurotoxicity and antioxidant activity was investigated to determine the effects of the extract on monoamine catabolism and neuroprotection. Ginkgo biloba leaf extract was shown to produce in-vitro inhibition of rat brain MAO-A and -B. The Ginkgo biloba extract was chromatographed on a reverse-phase HPLC system and two of the components isolated were shown to be MAO inhibitors (MAOIs). These MAOIs were identified by high-resolution mass spectrometry as kaempferol and isorhamnetin. Pure kaempferol and a number of related flavonoids were examined as MAOIs in-vitro. Kaempferol, apigenin and chrysin proved to be potent MAOIs, but produced more pronounced inhibition of MAO-A than MAO-B. IC50 (50% inhibition concentration) values for the ability of these three flavones to inhibit MAO-A were 7 x 10(-7), 1 x 10(-6) and 2 x 10(-6) M, respectively. Ginkgo biloba leaf extract and kaempferol were found to have no effect ex-vivo on rat or mouse brain MAO or on concentrations of dopamine, noradrenaline, 5-hydroxytryptamine and 5-hydroxyindoleacetic acid. Kaempferol was shown to protect against NMDA-induced neuronal toxicity in-vitro in rat cortical cultures, but did not prevent DSP-4-induced noradrenergic neurotoxicity in an in-vivo model. Both Ginkgo biloba extract and kaempferol were demonstrated to be antioxidants in a lipid-peroxidation assay. This data indicates that the MAO-inhibiting activity of Ginkgo biloba extract is primarily due to the presence of kaempferol. Ginkgo biloba extract has properties indicative of potential neuroprotective ability.
Asunto(s)
Flavonoides , Ginkgo biloba/química , Quempferoles , Inhibidores de la Monoaminooxidasa/análisis , Fármacos Neuroprotectores/farmacología , Extractos Vegetales/farmacología , Hojas de la Planta/química , Plantas Medicinales , Quercetina/análogos & derivados , Ácido 3,4-Dihidroxifenilacético/metabolismo , Administración Oral , Animales , Encéfalo/efectos de los fármacos , Encéfalo/enzimología , Encéfalo/metabolismo , Células Cultivadas , Cromatografía Líquida de Alta Presión , Dopamina/metabolismo , Relación Dosis-Respuesta a Droga , Ácido Hidroxiindolacético/metabolismo , Peroxidación de Lípido/efectos de los fármacos , Hígado/efectos de los fármacos , Hígado/enzimología , Masculino , Ratones , Monoaminooxidasa/efectos de los fármacos , Monoaminooxidasa/metabolismo , Inhibidores de la Monoaminooxidasa/farmacología , N-Metilaspartato/farmacología , Neuronas/citología , Neuronas/efectos de los fármacos , Norepinefrina/metabolismo , Extractos Vegetales/química , Quercetina/análisis , Quercetina/farmacología , Ratas , Ratas Sprague-Dawley , Serotonina/metabolismo , Células Tumorales Cultivadas/efectos de los fármacos , Células Tumorales Cultivadas/metabolismoRESUMEN
Double-labelling studies at the electron microscopic level demonstrated that gamma-aminobutyric acid (GABA)-immunoreactive nerve endings are associated with growth-hormone-secreting cells in the proximal pars distalis of the goldfish pituitary gland, suggesting that GABA may be important for the control of growth hormone release in this species. An in vitro assay for GABA-transaminase activity demonstrated that the pituitary is a site for the metabolism of GABA to succinic acid. In vitro, GABA or the GABA antagonists bicuculline and saclofen did not affect the rate of growth hormone release from dispersed pituitary cells in static incubation. In contrast, intracerebroventricular injection of GABA reduced serum growth hormone levels within 30 min. During the seasonal gonadal cycle, intraperitoneal injection of GABA was without effect in sexually regressed goldfish, but caused a significant decrease in serum growth hormone levels in sexually recrudescent animals. Intraperitoneal implantation of solid silastic pellets containing oestradiol increased serum GH levels fivefold in sexually regressed and recrudescent goldfish; in both groups, GABA suppressed the oestradiol-stimulated increase in circulating growth hormone levels. The effect of oestradiol on basal serum growth hormone levels was specific since progesterone and testosterone were without effect. However, in recrudescent animals treated with progesterone and testosterone, the inhibitory effects of GABA on serum growth hormone levels were absent, indicating a differential role for these steroids in growth hormone release. Taken together, these results demonstrate that GABA has an inhibitory effect on growth hormone release in goldfish.
Asunto(s)
Carpa Dorada/fisiología , Hormonas Esteroides Gonadales/farmacología , Hormona del Crecimiento/antagonistas & inhibidores , Hormona del Crecimiento/metabolismo , Ácido gamma-Aminobutírico/fisiología , 4-Aminobutirato Transaminasa/metabolismo , Animales , Células Cultivadas , Estradiol/administración & dosificación , Estradiol/farmacología , Femenino , Hormonas Esteroides Gonadales/administración & dosificación , Inmunohistoquímica , Inyecciones Intraperitoneales , Inyecciones Intraventriculares , Masculino , Adenohipófisis/citología , Adenohipófisis/efectos de los fármacos , Adenohipófisis/metabolismo , Progesterona/administración & dosificación , Progesterona/farmacología , Testosterona/administración & dosificación , Testosterona/farmacología , Ácido gamma-Aminobutírico/administración & dosificación , Ácido gamma-Aminobutírico/metabolismoRESUMEN
AIM: To determine the concentrations of chemical characteristic to extracts of leaves and flowers of Hypericum perforatum (St John's wort) in a number of selected samples and, following chemical characterization, to investigate the effects of these extracts on several pharmacological properties including effects of the extracts on inhibition of 5-hydroxytryptamine (5-HT) uptake and on antioxidant properties. METHODS: The samples were analyzed for the presence of characteristic chemicals by high performance liquid chromatography (HPLC) directly coupled to ultraviolet wavelength absorbance and positive or negative mode electrospray mass spectrometric detection. The effects of extracts on 5-HT uptake were determined by quantifying 3H-5-HT incorporation into rat hippocampal prisms. Estimates of effects of extracts on free radical scavenging capacity were made using a dynamic assay based on the ability of compounds to prevent the initiation of a colored reaction produced by the horseradish peroxidase catalyzed formation of hydroxyl free radicals from hydrogen peroxide using 2',2'-azinobis (3-ethylbenzthiazoline-6-sulfonic acid) as the color indicator. RESULTS: The chemical profile of a number of extracts were determined and found to differ substantially from each other. Inhibition of 5-HT uptake was found to correlate with hyperforin content and free radical scavenging capacity was found to correlate with the content of several flavonoids including quercetin and hyperoside. CONCLUSION: Standardized extracts of H perforatum varied substantially in the concentration of several characteristic chemicals. The correlation between pharmacological activity and certain characteristic chemicals found in these extracts indicates that the medicinal benefit derived from selected extracts will vary considerably depending on their chemical composition.
Asunto(s)
Hypericum/química , Perileno/análogos & derivados , Quercetina/análogos & derivados , Quercetina/farmacología , Terpenos/farmacología , Animales , Antracenos , Antioxidantes/farmacología , Compuestos Bicíclicos con Puentes , Depuradores de Radicales Libres/farmacología , Hipocampo/metabolismo , Masculino , Perileno/aislamiento & purificación , Perileno/farmacología , Floroglucinol/análogos & derivados , Quercetina/aislamiento & purificación , Ratas , Ratas Sprague-Dawley , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Terpenos/aislamiento & purificaciónRESUMEN
OBJECTIVE: To determine if HT-1001, an extract of American ginseng, affects scopolamine-induced memory and performance deficits in a spatial learning task, alters brain concentrations of aminergic neurotransmitters, and alters choline uptake in synaptosome preparations. DESIGN: Animal study. ANIMALS: 48 Sprague Dawley rats. INTERVENTIONS: Long-term oral administration of a test material or control solution. Intraperitoneal administration of scopolamine (2 mg/kg) 30 minutes before testing. OUTCOME MEASURES: Performance on Morris water maze task, choline uptake, aminergic neurotransmitter analysis, in vitro monoamine oxidase analysis (of compounds). RESULTS: HT-1001 protected against scopolamine-induced amnesia and increased choline uptake in synaptosomal preparations. HT-1001 did not alter brain concentrations of norepinephrine, dopamine, 5-HT (serotonin), 3,4-dihydroxyphenylacetic acid or 5-hydroxyindoleactic acid. HT-1001 had a very weak ability to inhibit monoamine oxidase activity in vitro. CONCLUSIONS: HT-1001 demonstrates a capacity to protect against scopolamine-induced memory deficits.
Asunto(s)
Fármacos del Sistema Nervioso Central/farmacología , Aprendizaje por Laberinto/efectos de los fármacos , Recuerdo Mental/efectos de los fármacos , Orientación/efectos de los fármacos , Panax , Plantas Medicinales , Saponinas/farmacología , Escopolamina/toxicidad , Animales , Ginsenósidos , Masculino , Ratas , Ratas Sprague-DawleyRESUMEN
High levels of the amino acid neurotransmitter glutamate were found in the goldfish hypothalamus and pituitary using high performance liquid chromatography with fluorometric detection. A specific polyclonal antibody to glutamate was generated in the rabbit for immunocytochemistry. Localization studies demonstrated that glutamatergic neurons of undetermined origin innervate the particular part of the goldfish adenohypophysis where somatotrophs and gonadotrophs are located. Intraperitoneal and brain third ventricle injection of the glutamate agonist N-methyl-D,L-aspartic acid (NMA) inhibited GH release in vivo. The gonadal steroid estradiol plays an important role in regulating GH secretion by stimulating basal serum GH levels and enhancing the inhibitory effects of NMA on GH secretion. Taken together, these results demonstrate that glutamate is an important regulator of GH secretion in goldfish.
Asunto(s)
Ácido Glutámico/farmacología , Carpa Dorada/fisiología , Hormona del Crecimiento/metabolismo , N-Metilaspartato/farmacología , Animales , Estradiol/farmacología , Ácido Glutámico/análisis , Inmunohistoquímica , Inyecciones Intraventriculares , N-Metilaspartato/administración & dosificación , Hipófisis/químicaRESUMEN
Previous studies have shown that in select neurons, neurite outgrowth can be regulated by the same neurotransmitter that is synthesized and released by those neurons. However, it is not known whether such an autoregulatory mechanism is utilized during the normal course of nervous system development in either invertebrates or vertebrates. In the present study, we tested this hypothesis on the first pair of identified serotonergic neurons to be expressed in embryos of the pulmonate gastropod, Helisoma trivolvis. Embryonic neurons C1 (ENC1) elaborate a stereotyped pattern of neurite outgrowth prior to the differentiation of subsequent serotonergic neurons. Embryos were treated with either p-chlorophenylalanine (pCPA) or 5-hydroxytryptophan (5-HTP) to lower or raise embryonic serotonin content, respectively. High-performance liquid chromatography with electrochemical detection was used to measure the effects of these treatments on serotonin content, and serotonin immunohistochemistry was carried out to quantify the extent of neurite outgrowth of ENC1. Embryonic serotonin content was significantly reduced at both 24 and 48 hr after treatment with 0.02% pCPA, whereas dopamine levels were unchanged. Although the proximal neurite outgrowth of ENC1 appeared unaffected by the pCPA treatment at both of these time points, the distal outgrowth in the target cell region appeared more profuse. This effect on outgrowth was quantified by counting the number of neurite branch points, which was significantly increased both 24 and 48 hr after pCPA treatment. In contrast, 5-HTP treatment resulted in an increase in embryonic serotonin content and a significant decrease in the number of ENC1 branch points. Treatment with dopamine had no effect on the pattern of ENC1 neurite outgrowth. Together, these results support the hypothesis that a neuron may utilize its own transmitter in an autoregulatory fashion to regulate neurite formation during embryonic development.
Asunto(s)
Homeostasis , Neuritas/fisiología , Neuronas/química , Serotonina/análisis , Caracoles/embriología , 5-Hidroxitriptófano/farmacología , Animales , Autorreceptores/fisiología , Fenclonina/farmacología , Inmunohistoquímica , Receptores de Serotonina/fisiología , Serotonina/fisiologíaRESUMEN
Phenelzine (PLZ), a frequently prescribed monoamine oxidase (MAO) inhibitor, is used as an antidepressant/antipanic drug and has been shown to cause marked increases in rat brain levels of the amino acids gamma-aminobutyric acid (GABA) and alanine. In an extension of previous studies related to GABA metabolism, we investigated the effects of PLZ on rat brain levels of glutamine (GLN). At 1, 3 or 6 h after injection of PLZ (15 mg kg-1 i.p.), rats were killed and the brains removed. Analyses (using HPLC with fluorescence detection of OPT derivatives) of whole brain or hypothalamus revealed a decrease in brain levels of GLN and an increase in GABA levels at 3 and 6 h after PLZ injection. The effects of PLZ on GLN and GABA were blocked by prior treatment of the rats with tranylcypromine, a MAO inhibitor that had been shown previously to have no direct effect itself on GABA levels in rat brain. Since PLZ is known to be a substrate (as well as an inhibitor) of MAO, the studies with tranylcypromine pretreatment suggest that the effects on GLN and GABA are caused, at least in part, by a metabolite of PLZ.
Asunto(s)
Encéfalo/efectos de los fármacos , Glutamina/análisis , Inhibidores de la Monoaminooxidasa/farmacología , Fenelzina/farmacología , Ácido gamma-Aminobutírico/análisis , Animales , Química Encefálica , Hipotálamo/efectos de los fármacos , Masculino , Ratas , Ratas Sprague-DawleyRESUMEN
Episodes of short high intensity exercise are associated with an increase in circulating total testosterone (T) in men. Mechanisms may include hemoconcentration, decreased metabolic clearance and/or increased synthesis. Beta-blockade abolishes the T response suggesting a direct beta-adrenergic effect on the testes. Some spinal cord injured (SCI) athletes deliberately induce autonomic dysreflexia (boosting) to enhance performance. Associated with this practice are elevated catecholamine (CA) levels and exaggerated responses to serum catecholamine levels. Since basal T levels are reported to be normal in the SCI male, the T response to acute high intensity exercise might be expected to be exaggerated by boosting and associated elevated CA levels. The acute exercise T response has not been examined in SCI men to date. To determine whether the increased CA values associated with boosting enhanced the exercise-induced T elevation we measured circulating levels of T, cortisol (C), norepinephrine (NE) and epinephrine (E) before and after maximal exertion and a simulated 7.5 km race with and without boosting in eight elite quadriplegic athletes. Maximal incremental exercise and a simulated 7.5 km race resulted in a rise in T similar to able bodied men under normal exercise conditions. Under boosted conditions the rise in T was eliminated while NE levels were significantly elevated above unboosted levels. The data may suggest an inhibitory role for CA on T production or release under conditions of extreme stress. Other possible mechanisms include C induced suppression, impaired gonadotropin stimulation of the Leydig cell and CA mediated alterations in gonadal blood supply.
Asunto(s)
Enfermedades del Sistema Nervioso Autónomo/fisiopatología , Catecolaminas/sangre , Ejercicio Físico/fisiología , Hidrocortisona/sangre , Cuadriplejía/fisiopatología , Estrés Fisiológico/fisiopatología , Testosterona/sangre , Aerobiosis , Enfermedades del Sistema Nervioso Autónomo/sangre , Presión Sanguínea/fisiología , Cromatografía Líquida de Alta Presión , Humanos , Masculino , Cuadriplejía/sangre , Reflejo/fisiología , Estrés Fisiológico/sangre , Vejiga Urinaria/fisiopatologíaRESUMEN
The conversion of 5-hydroxytryptamine to several potential metabolites was examined in the annelid earthworm (Lumbricus terrestris). 5-hydroxytryptamine and some related amines were found to be present in several tissues of the earthworm. Injection of 5-hydroxytryptamine into the body cavity of the earthworm resulted in the production of a gamma-glutamyl conjugate of 5-hydroxytryptamine. Incubations of the anterior nerve cord of the earthworm resulted in the accumulation of considerable amounts of 5-hydroxytryptamine and gamma-glutamyl 5-hydroxytryptamine in the incubation medium. The earthworm did not produce any N-acetyl 5-hydroxytryptamine and only very little 5-hydroxyindoleacetic acid. Experiments involving the injection of radiolabeled 5-hydroxytryptamine or coinjection of radiolabeled glutamic acid with unlabeled 5-hydroxytryptamine into the earthworm resulted in the production of radiolabeled gamma-glutamyl 5-hydroxytryptamine. This work demonstrates that the enzymatic conversion of 5-HT in the earthworm is markedly different from that of vertebrates and insects.
Asunto(s)
Acetiltransferasas/metabolismo , Monoaminooxidasa/metabolismo , Oligoquetos/metabolismo , Serotonina/análogos & derivados , Serotonina/metabolismo , Sulfotransferasas/metabolismo , gamma-Glutamiltransferasa/metabolismo , Animales , Cromatografía Líquida de Alta PresiónRESUMEN
It is known that norepinephrine (NE) is important in the neuroendocrine control of pituitary gonadotropin II (GTH-II) and growth hormone (GH) release but very little is known about the factors regulating NE neurons in the goldfish brain. Female gonad-intact goldfish were implanted intraperitoneally (100 micrograms/g) with testosterone (T) or estradiol (E2) to elevate serum steroid levels. High-performance liquid chromatography measurements showed that steroid implantation had no effect on NE content in the telencephalon, including preoptic area (TEL-POA), or the hypothalamus (HYP). The turnover rate of NE was estimated from the rate of depletion of NE content from tissues following inhibition of tyrosine hydroxylase by alpha-methyl-p-tyrosine (240 micrograms/g). The present study demonstrates that E2 can decrease NE turnover rates in TEL-POA and HYP of sexually regressed goldfish (August). The results in recrudescent fish (November), however, indicate a more complex interaction of E2 with NE neurons since E2 increased NE turnover in TEL-POA and HYP in these animals. Testosterone (T) has less prominent effects on NE turnover rates in TEL-POA and HYP; the only significant effect of T-implantation was a small reduction of NE turnover in the TEL-POA of sexually recrudescent fish. Elevation of endogenous brain GABA concentrations by injection of the GABA transaminase inhibitor, gamma-vinyl-GABA (300 micrograms/g), significantly reduced NE turnover in TEL-POA. These data demonstrate that goldfish NE neurons in the TEL-POA are sensitive to regulation by changes in circulating sex steroids and by increases in brain GABA.
Asunto(s)
Encéfalo/metabolismo , Estradiol/farmacología , Carpa Dorada/metabolismo , Norepinefrina/metabolismo , Testosterona/farmacología , Ácido gamma-Aminobutírico/fisiología , 4-Aminobutirato Transaminasa/antagonistas & inhibidores , Aminocaproatos/farmacología , Animales , Cromatografía Líquida de Alta Presión , Implantes de Medicamentos , Femenino , Peritoneo , Maduración Sexual/fisiología , Distribución Tisular , VigabatrinRESUMEN
The involvement of gamma-aminobutyric acid (GABA) in regulation of pituitary gonadotropin-II (GTH-II) release was studied in the goldfish. Intraperitoneal injection of GABA (300 micrograms/g) stimulated an increase in serum GTH-II levels at 30 min postinjection. The GABAA receptor agonist muscimol (0.1-10 micrograms/g) stimulated GTH-II in a dose-dependent manner. Baclofen, a GABAB receptor agonist, had a small but significant stimulatory effect at 1 and 10 micrograms/g; the amount of GTH-II released in response to baclofen was significantly less (P < 0.05) than that released by muscimol. Pretreatment of goldfish with bicuculline, a GABAA receptor antagonist, but not saclofen, a GABAB receptor antagonist, blocked the stimulatory effect of GABA on serum GTH-II. Elevation of brain and pituitary GABA levels with the GABA transaminase inhibitor, gamma-vinyl-GABA (GVG), decreased hypothalamic and pituitary dopamine (DA) turnover rates, indicating that GABA may stimulate GTH-II release in the goldfish by decreasing dopaminergic inhibition of GTH-II release. The release of GTH-II stimulated by muscimol and GVG was potentiated by pharmacological agents that decrease inhibitory dopaminergic tone, indicating that DA may also inhibit GABA-stimulated GTH-II release. Based on the linear 24-h accumulation of GABA in brain and pituitary after GVG injection, implantation of testosterone, estradiol, or progesterone, previously shown to regulate the serum GTH-II release response to gonadotropin-releasing hormone and GABA, was also found to modulate GABA synthesis in the brain and pituitary.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Dopamina/fisiología , Carpa Dorada/metabolismo , Hormonas Esteroides Gonadales/fisiología , Gonadotropinas/metabolismo , Receptores de GABA-A/fisiología , Ácido gamma-Aminobutírico/farmacología , Aminocaproatos/farmacología , Animales , Encéfalo/metabolismo , Antagonistas de Receptores de GABA-A , Gonadotropinas/sangre , Hipófisis/metabolismo , VigabatrinRESUMEN
The effects of gonadal steroids on GABA-, taurine (TAU)- and N-methyl-D,L-aspartate (NMA)-induced gonadotropin-II (GTH-II) release were investigated in male and female goldfish in vivo. In sexually regressed goldfish (both sexes mixed), intraperitoneal implantation for 5 to 10 days with solid Silastic pellets containing testosterone (100 micrograms/g), oestradiol (100 micrograms/g) or progesterone (100 micrograms/g) was previously shown to elevate serum sex steroid levels to values comparable to those in sexually mature animals, and to potentiate gonadotropin-releasing hormone-stimulated GTH-II release. In the present study, testosterone but not oestradiol or progesterone enhanced the stimulatory effects of exogenous GABA (100 micrograms/g) on GTH-II release in vivo. TAU (1 mg/g) stimulated GTH-II release in sexually regressed mixed sex and sexually recrudescent male goldfish, and both testosterone and oestradiol implantation enhanced GTH-II release induced by TAU. The glutamate agonist NMA (25 to 50 micrograms/g) was also found to stimulate GTH-II release; however it was relatively less effective in elevating serum GTH-II levels than GABA and TAU, and its effects were not modulated by sex steroid treatments. Pretreatment of goldfish with alpha-methyl-p-tyrosine to deplete brain and pituitary catecholamines did not affect NMA action on GTH-II release. Our results indicate that GABA, TAU and NMA are involved in the neuroendocrine regulation of GTH-II release in goldfish, and support the idea that testosterone participates in the positive feedback regulation of pituitary gonadotropin release in a non-mammalian vertebrate by enhancing GABA- and TAU-stimulated GTH release in vivo.
Asunto(s)
Carpa Dorada/fisiología , Gonadotropinas/metabolismo , N-Metilaspartato/farmacología , Taurina/farmacología , Testosterona/farmacología , Ácido gamma-Aminobutírico/farmacología , Animales , Química Encefálica/efectos de los fármacos , Implantes de Medicamentos , Estradiol/farmacología , Retroalimentación/fisiología , Femenino , Masculino , Metiltirosinas/farmacología , Progesterona/farmacología , Radioinmunoensayo , Testosterona/administración & dosificación , Tirosina 3-Monooxigenasa/metabolismo , alfa-Metiltirosina , Ácido gamma-Aminobutírico/administración & dosificaciónRESUMEN
The parathyroid hormone (PTH) gene is expressed and translated in the rat hypothalamus, and the possibility that PTH may modulate neural activity was therefore examined in anesthetized rats. Intracerebroventricular (ICV) injections of 1.0 or 10.0 micrograms rat, human, or bovine PTH(1-34) was followed 60 min later by increased concentrations of DOPAC (dihydroxyacetic acid) and the DOPAC:dopamine (DA) ratio in the medial basal hypothalamus (MBH), but not in other (brainstem, cerebral cortex, cerebellum) regions of the brain. Tissue concentrations of norepinephrine and serotonin were unchanged by ICV PTH administration, although MBH concentrations of 5-hydroxyindolacetic acid (5-HIAA) were increased following PTH administration. An increase in MBH DA turnover (as indicated by an increased DOPAC:DA ratio) was also induced by the ICV injection of 10 micrograms PTH-related protein [PTHrP(1-34)]. Pretreatment with the receptor antagonists PTH(7-34) or PTHrP(7-34) completely blocked the subsequent DOPAC response to ICV PTH or PTHrP, respectively. The DOPAC concentrations in hypothalamic extracellular fluid (ECF), sampled by microdialysis, were also increased within 20 min of PTH(1-34) perfusion, in the absence of changes in the ECF concentrations of 5-HIAA. These results demonstrate that PTH and PTH-like peptides specifically increase DA turnover in the rat MBH and suggest novel roles for these hormones in neural regulation.
Asunto(s)
Dopamina/metabolismo , Hipotálamo Medio/efectos de los fármacos , Hormona Paratiroidea/farmacología , Fragmentos de Péptidos/farmacología , Ácido 3,4-Dihidroxifenilacético/metabolismo , Animales , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Hipotálamo Medio/metabolismo , Inyecciones Intraventriculares , Masculino , Hormona Paratiroidea/administración & dosificación , Hormona Paratiroidea/metabolismo , Fragmentos de Péptidos/administración & dosificación , Fragmentos de Péptidos/metabolismo , Ratas , Ratas Sprague-Dawley , Teriparatido , Distribución TisularRESUMEN
The catabolism of intracerebroventricularly injected 5-hydroxytryptamine in mouse brain was investigated. Pretreatment of animals with the 5-hydroxytryptamine type 1 receptor antagonist metergoline, the 5-hydroxytryptamine type 2 receptor antagonist ketanserin, the 5-hydroxytryptamine reuptake inhibitor fluoxetine, or the selective 5-hydroxytryptamine neurotoxin 5,7-dihydroxytryptamine failed to alter the rate of catabolism of intracerebroventricularly administered 5-hydroxytryptamine. The monoamine oxidase inhibitor tranylcypromine effectively blocked degradation of injected 5-hydroxytryptamine and accumulation of 5-hydroxyindoleacetic acid. Coinjection of tryptamine with 5-hydroxytryptamine reduced the rate of conversion of 5-hydroxytryptamine to 5-hydroxyindoleacetic acid. These results indicate that intracerebroventricularly administered 5-hydroxytryptamine is removed by a monoamine oxidase dependent system. This catabolism is not affected by inhibition of presynaptic uptake, 5-hydroxytryptamine receptor type 1 or type 2 blockade, or destruction of serotonergic nerve terminals. The coadministration of tryptamine may prolong the residence period of 5-hydroxytryptamine through competition for monoamine oxidase.
Asunto(s)
Serotonina/metabolismo , Triptaminas/farmacología , Animales , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Catálisis , Fluoxetina/farmacología , Inyecciones Intraventriculares , Ketanserina/farmacología , Masculino , Metergolina/farmacología , Ratones , Neuronas/metabolismo , Serotonina/administración & dosificación , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Factores de Tiempo , Triptaminas/administración & dosificaciónRESUMEN
The effects of gonadal steroids on the gonadotropin (GTH) release response to salmon gonadotropin-releasing hormone (sGnRH), chicken gonadotropin-releasing hormone-II (cGnRH-II), and the sGnRH analogue, [D-Arg6, Trp7, Leu epsilon, Pro9]-N-ethylamide-GnRH (sGnRH-A), were investigated using an in vitro perifusion system for goldfish pituitary fragments. Gonad-intact male and female goldfish were implanted intraperitoneally (i.p.) with silastic pellets containing no steroid (blank), testosterone (T; 100 micrograms/g), or estradiol (E2; 100 micrograms/g); pituitaries were removed 5 days later for perifusion experiments. In vivo treatment with T or E2 potentiates sGnRH-, cGnRH-II-, and sGnRH-A-induced GTH secretion from pituitary fragments of sexually regressed and sexually recrudescent goldfish in vitro. Testosterone (100 nM; 24 h) treatment in vitro has a direct effect on the pituitary to increase sGnRH responsiveness, and this potentiating effect of T was blocked by the protein synthesis inhibitor cycloheximide (25 microM). In sexually regressed goldfish, in vivo T implantation enhanced the serum GTH response to sGnRH-A (0.01 microgram/g; 6 h) 7-fold. ED50 estimates for in vitro pituitary GTH responsiveness to sGnRH-A were 1.0 +/- 0.1 nM and 0.1 +/- 0.1 nM (p < 0.05) for blank and T-implanted groups, respectively. Radioligand (125I-sGnRH-A) binding studies demonstrated that enhanced pituitary responsiveness was independent of changes in pituitary GnRH receptor affinity or number. These results demonstrate that sex steroids increase pituitary sensitivity to GnRH peptides in the goldfish.
Asunto(s)
Estradiol/farmacología , Carpa Dorada/fisiología , Hormona Liberadora de Gonadotropina/farmacología , Gonadotropinas/metabolismo , Hipófisis/metabolismo , Testosterona/farmacología , Animales , Cicloheximida/farmacología , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Femenino , Hormona Liberadora de Gonadotropina/análogos & derivados , Técnicas In Vitro , Masculino , Hipófisis/efectos de los fármacos , Radioinmunoensayo , Receptores LHRH/metabolismoRESUMEN
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 1-methyl-4-phenylpyridinium iodide (MPP+) and gamma-vinyl-gamma-aminobutyric acid (gamma-vinyl GABA) are drugs demonstrated to alter catecholamine or gamma-aminobutyric acid (GABA) concentrations in vertebrate nervous tissue. MPTP and MPP+, which are potent and selective vertebrate neurotoxins, are effective in depleting noradrenaline and dopamine concentrations in goldfish. However, only MPP+ depletes dopamine in the central nervous tissues of the cockroach, and only when injected directly into the nervous tissue. Systemic injection of gamma-vinyl GABA, a selective GABA transaminase inhibitor in vertebrates, increases GABA concentrations in goldfish but not cockroach nervous tissue. Incubations of both goldfish hypothalamus and cockroach nervous tissue demonstrated the presence of GABA transaminase activity in vitro. However, the GABA transaminase activity obtained from goldfish tissues was much more sensitive to inhibition by gamma-vinyl GABA than that obtained from cockroach nervous tissue. These results demonstrate that MPTP, MPP+ and gamma-vinyl GABA are useful pharmacological tools which can alter neurotransmitter concentrations in a lower vertebrate. Unfortunately, they possess limited effectiveness in the cockroach.
Asunto(s)
1-Metil-4-fenil-1,2,3,6-Tetrahidropiridina/farmacología , Aminocaproatos/farmacología , Cucarachas/metabolismo , Carpa Dorada/metabolismo , Sistema Nervioso/metabolismo , Neurotransmisores/metabolismo , 1-Metil-4-fenilpiridinio/farmacología , 4-Aminobutirato Transaminasa/antagonistas & inhibidores , Animales , Dopamina/metabolismo , Ganglios/metabolismo , Masculino , Sistema Nervioso/efectos de los fármacos , Norepinefrina/metabolismo , Hipófisis/metabolismo , Vigabatrin , Ácido gamma-Aminobutírico/metabolismoRESUMEN
In goldfish it is known that intraperitoneal implantation with testosterone (T) or estradiol (E2) potentiates the serum gonadotropin-II (GtH-II) response to gonadotropin-releasing hormone (GnRH) without affecting basal GtH-II levels. Since the release of GtH-II in goldfish is under a tonic dopaminergic inhibitory tone, the possibility of sex steroids modulating brain and pituitary dopamine was examined in vivo and in vitro. Implantation of females with either T or E2 (100 micrograms/g in solid silastic pellets) also potentiated the increase in serum GtH-II in response to the dopamine antagonist, domperidone (10 micrograms/g). High-performance liquid chromatography measurements showed that steroid implantation had no effect on dopamine content in the telencephalon including preoptic area, hypothalamus, and pituitary. However, the present study demonstrates that T or E2 can increase pituitary dopamine turnover rates following tyrosine hydroxylase inhibition with alpha-methyl-p-tyrosine (240 micrograms/g). In vitro perifusion of pars distalis fragments from E2- or T-treated fish also showed a potentiation of salmon GnRH (sGnRH)-induced GtH-II release compared to controls. However, exposure to pituitary fragments from control and steroid-treated fish to increasing doses of the dopamine agonist LY 171555 did not demonstrate a significant difference in the sensitivity of the gonadotrophs to dopamine. Testosterone-induced alterations in DA turnover are dissociable from the positive action of T on pituitary responsiveness, since the potentiating effect of T implantation was not affected by severe depletion of brain and pituitary DA levels by alpha-methyl-p-tyrosine pretreatment. These data demonstrate that in gonad-intact goldfish, sex steroids enhance pituitary responsiveness to GnRH but basal serum GtH-II levels are maintained by a concomitant increase in DA turnover in the pituitary.